Abstract
The hormonally active form of vitamin D3, 1α,25-dihydroxyvitamin D3 (1a), has a wide variety of biological activities and its major molecular target is considered to be the vitamin D receptor (VDR). The A-ring stereoisomers of 1a as well as its C2-modified analogues, which have different stereochemistry at the C1 and/or C3 hydroxy groups, are of interest since recent metabolic studies have shown that catabolism could occur through A-ring modification. In this review, a practical and versatile synthesis of the A-ring enyne precursors by the convergent method of Trost and coworkers, which is needed to construct all possible A-ring stereoisomers of 1,25-dihydroxyvitamin D3 (1a-d), and the C2-modified analogues (4a-d, 5a-d, 6a-d and 7a-d) is described. A strategy for the synthesis and evaluation of all possible A-ring stereoisomers of 1a and their A-ring modified analogues is important, and this will stimulate synthesis and biological studies into vitamin D.
Keywords: Analogue, Chemical synthesis, Hormone, Nuclear receptor, Steroid, Vitamin.
Current Topics in Medicinal Chemistry
Title:Synthetic Strategy and Biological Activity of A-ring Stereoisomers of 1,25- Dihydroxyvitamin D3 and C2-Modified Analogues
Volume: 14 Issue: 21
Author(s): Toshie Fujishima, Tsutomu Suenaga and Takato Nozaki
Affiliation:
Keywords: Analogue, Chemical synthesis, Hormone, Nuclear receptor, Steroid, Vitamin.
Abstract: The hormonally active form of vitamin D3, 1α,25-dihydroxyvitamin D3 (1a), has a wide variety of biological activities and its major molecular target is considered to be the vitamin D receptor (VDR). The A-ring stereoisomers of 1a as well as its C2-modified analogues, which have different stereochemistry at the C1 and/or C3 hydroxy groups, are of interest since recent metabolic studies have shown that catabolism could occur through A-ring modification. In this review, a practical and versatile synthesis of the A-ring enyne precursors by the convergent method of Trost and coworkers, which is needed to construct all possible A-ring stereoisomers of 1,25-dihydroxyvitamin D3 (1a-d), and the C2-modified analogues (4a-d, 5a-d, 6a-d and 7a-d) is described. A strategy for the synthesis and evaluation of all possible A-ring stereoisomers of 1a and their A-ring modified analogues is important, and this will stimulate synthesis and biological studies into vitamin D.
Export Options
About this article
Cite this article as:
Fujishima Toshie, Suenaga Tsutomu and Nozaki Takato, Synthetic Strategy and Biological Activity of A-ring Stereoisomers of 1,25- Dihydroxyvitamin D3 and C2-Modified Analogues, Current Topics in Medicinal Chemistry 2014; 14 (21) . https://dx.doi.org/10.2174/1568026615666141208102907
DOI https://dx.doi.org/10.2174/1568026615666141208102907 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Translocator Protein (TSPO) in Breast Cancer
Current Molecular Medicine Neurotrophins - From Pathophysiology to Treatment in Alzheimers Disease
Current Alzheimer Research Plasticizers in Food and Beverages
Current Analytical Chemistry The Role of Components of the Lymphoreticular System in Transmissible Spongiform Encephalopathy Pathogenesis and Neuroinvasion
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Hepatocyte Growth Factor (HGF) for a Cell-Signal-Based Therapy During Acute and Chronic Liver Diseases
Current Signal Transduction Therapy Phytochemicals to Prevent Inflammation and Allergy
Recent Patents on Inflammation & Allergy Drug Discovery Approaches to the Pharmacological Modulation of Plasmacytoid Dendritic Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Adiposity and the Gut - The Role of Gut Hormones
Current Nutrition & Food Science Recent Updates on Glucokinase Activators for the Treatment of Type 2 Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Integrins and Cancer: Gene Expression, Epigenetics and Metastasis
Current Genomics New Opportunities for Pregnane X Receptor (PXR) Targeting in Drug Development. Lessons from Enantio- and Species-Specific PXR Ligands Identified from A Discovery Library of Amino Acid Analogues
Mini-Reviews in Medicinal Chemistry Osteoporosis in Patients with Breast and Prostate Cancer: Effect of Disease and Treatment Modalities
Endocrine, Metabolic & Immune Disorders - Drug Targets Niacin Status, NAD Distribution and ADP-Ribose Metabolism
Current Pharmaceutical Design Nuclear Factor Erythroid 2 - Related Factor 2 Signaling in Parkinson Disease: A Promising Multi Therapeutic Target Against Oxidative Stress, Neuroinflammation and Cell Death
CNS & Neurological Disorders - Drug Targets Microfluidic Devices for Cell, Tissue and Embryo Culture
Recent Patents on Regenerative Medicine Oxidized Haemoglobin–Driven Endothelial Dysfunction and Immune Cell Activation: Novel Therapeutic Targets for Atherosclerosis
Current Medicinal Chemistry Proteinn-X, Pancreatic Stone-, Pancreatic Thread-, reg-Protein, P19, Lithostathine, and Now What
Current Protein & Peptide Science Possible Therapeutic Uses of Extracellular Vesicles for Reversion of Activated Hepatic Stellate Cells: Context and Future Perspectives
Current Molecular Medicine Risk and Benefit Profile of Dulaglutide in Established Therapeutic Indication
Current Drug Safety